Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2009-09-21
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well
it works in treating young patients with solid tumors or anaplastic large cell lymphoma that
has returned after a period of improvement or does not respond to treatment. Crizotinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
(Phase 1 completed 2/15/13)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Completed
Pfizer
Phase 1/Phase 2
2009-09-21
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well
it works in treating young patients with solid tumors or anaplastic large cell lymphoma that
has returned after a period of improvement or does not respond to treatment. Crizotinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
(Phase 1 completed 2/15/13)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Completed
Children's Oncology Group
Phase 1/Phase 2
2009-09-21
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well
it works in treating young patients with solid tumors or anaplastic large cell lymphoma that
has returned after a period of improvement or does not respond to treatment. Crizotinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
(Phase 1 completed 2/15/13)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
